Discusses combinatorial in situ cancer vaccination approaches that transform tumors into antigen sources and combine adjuvants and delivery technologies to boost systemic antitumor immunity.
Key Takeaways
- Therapeutic efficacy of this approach arises from the coordinated activation of multiple immune mechanisms
- These innovations position in situ cancer vaccination as a patient-tailored
- Recent clinical investigations have underscored the therapeutic potential of in situ vaccination